Pivotal studies and post hoc analyses of these studies have shown that mepolizumab is effective at eosinophil values of 150 cells/µL and above. Whether these benefits are also maintained in real life is of interest.

REDES is a real-life study performed in Spain that evaluated the effectiveness and safety of mepolizumab in severe eosinophilic asthma that incorporates a prespecified stratification by blood eosinophil counts for outcomes analysis.

Mepolizumab reduced severe exacerbations and oral corticosteroid consumption, and improved asthma control. These benefits occurred irrespective of baseline eosinophil counts.

No severe adverse events related to mepolizumab were reported.